EP0701563A4 - Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote - Google Patents

Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote

Info

Publication number
EP0701563A4
EP0701563A4 EP94910861A EP94910861A EP0701563A4 EP 0701563 A4 EP0701563 A4 EP 0701563A4 EP 94910861 A EP94910861 A EP 94910861A EP 94910861 A EP94910861 A EP 94910861A EP 0701563 A4 EP0701563 A4 EP 0701563A4
Authority
EP
European Patent Office
Prior art keywords
product
gene encoding
mammalian host
cell
connective tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94910861A
Other languages
German (de)
English (en)
Other versions
EP0701563A1 (fr
Inventor
Joseph C Glorioso
Christopher H Evans
Paul D Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP0701563A1 publication Critical patent/EP0701563A1/fr
Publication of EP0701563A4 publication Critical patent/EP0701563A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à un procédé permettant d'introduire au moins un gène codant un produit dans au moins une cellule d'un tissu conjonctif d'un mammifère hôte afin de traiter ce dernier. Ce procédé consiste à utiliser des techniques de recombinaison pour produire une molécule vecteur d'ADN contenant le gène codant pour le produit, et à infecter la cellule conjonctive du mammifère hôte au moyen de la molécule vecteur d'ADN comprenant le gène codant pour le produit. L'invention se rapporte également à un procédé permettant d'introduire au moins une cellule d'un tissu conjonctif d'un mammifère hôte par une voie non virale. Un procédé de production d'un modèle animal destiné à l'étude de la pathologie des tissus conjonctifs est également décrit, ainsi qu'un procédé d'utilisation in vivo d'un gène codant un domaine de liaison d'interleukine-1 extracellulaire d'un récepteur d'interleukine-1.
EP94910861A 1993-03-08 1994-03-07 Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote Withdrawn EP0701563A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2775093A 1993-03-08 1993-03-08
US27750 1993-03-08
PCT/US1994/002414 WO1994020517A1 (fr) 1993-03-08 1994-03-07 Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote

Publications (2)

Publication Number Publication Date
EP0701563A1 EP0701563A1 (fr) 1996-03-20
EP0701563A4 true EP0701563A4 (fr) 1997-07-02

Family

ID=21839568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94910861A Withdrawn EP0701563A4 (fr) 1993-03-08 1994-03-07 Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote

Country Status (4)

Country Link
EP (1) EP0701563A4 (fr)
JP (1) JPH08511507A (fr)
CA (1) CA2157782A1 (fr)
WO (1) WO1994020517A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
AU684050B2 (en) * 1992-07-13 1997-12-04 Baylor College Of Medicine Targeting somatic gene therapy to joints
WO1995016353A1 (fr) * 1993-12-14 1995-06-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Traitement systemique par genes des affections des tissus conjonctifs
JPH10508743A (ja) * 1994-09-09 1998-09-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド インターロイキン−１ タイプ３レセプター
US6239268B1 (en) 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
ES2099029B1 (es) * 1994-12-29 1998-01-01 Boeheringer Ingelheim Espana S Empleo del plasmido pmamafgf para preparar farmacos vasorrelajantes y antihipertensivos.
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
CA2273852C (fr) 1996-12-06 2009-09-29 Amgen Inc. Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
EP1009444A2 (fr) * 1997-09-02 2000-06-21 Chiron Corporation Compositions et methodes de traitement de l'arthrite par therapie genique
EP1939300A1 (fr) 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3081081B1 (fr) * 2013-12-12 2018-05-23 Mie University Mammifère transgénique non humain exprimant la protéine humaine mmp2
WO2015191783A2 (fr) 2014-06-10 2015-12-17 Abbvie Inc. Biomarqueurs des maladies inflammatoires et leurs procédés d'utilisation
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3836954B1 (fr) 2018-08-13 2025-05-07 Iltoo Pharma Combinaison d'interleukine-2 avec un inhibiteur de l'interleukine 1, conjugués et leurs utilisations thérapeutiques
JP2023548746A (ja) 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176170A1 (fr) * 1984-06-04 1986-04-02 Pasteur Merieux Serums Et Vaccins Virus Herpès simplex à titre de vecteur
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique
WO1992011359A1 (fr) * 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319071A (en) * 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5180182A (en) * 1991-08-26 1993-01-19 Haworth James R Trailer hitch alignment device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176170A1 (fr) * 1984-06-04 1986-04-02 Pasteur Merieux Serums Et Vaccins Virus Herpès simplex à titre de vecteur
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique
WO1992011359A1 (fr) * 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BANDARA, G. ET AL: "Gene transfer to synoviocytes: prospects for gene treatment of arthritis", DNA CELL BIOL. (1992), 11(3), 227-31 CODEN: DCEBE8;ISSN: 1044-5498, 1992, XP000671125 *
BANDARA, G. ET AL: "Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer", PROC. NATL. ACAD. SCI. U. S. A. (1993), 90(22), 10764-8 CODEN: PNASA6;ISSN: 0027-8424, 1993, XP002029933 *
BLAKE J. ROESSLER ET AL.: "Adenoviral-mediated gene transfer to rabbit synovium in vivo", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 92, no. 2, August 1993 (1993-08-01), pages 1085 - 1092, XP000671409 *
EVANS C H ET AL.: "Gene transfer to joints for arthritis therapy", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 16, no. F, April 1992 (1992-04-01), pages 46, XP000566580 *
EVANS C H ET AL: "SYNOVIAL CELL TRANSPLANTS FOR GENE TRANSFER TO JOINTS.", FIRST INTERNATIONAL CONGRESS OF THE CELL TRANSPLANT SOCIETY, PITTSBURGH, PENNSYLVANIA, USA, MAY 31-JUNE 3, 1992. TRANSPLANT PROC 24 (6). 1992. 2966. CODEN: TRPPA8 ISSN: 0041-1345, XP000577114 *
G. BANDARA ET AL.: "Intraarticular expression of IRAP by gene transfer", ARTHRITIS AND RHEUMATISM, vol. 35, no. 9, September 1992 (1992-09-01), pages S193, XP000563856 *
HUNG, G.L. ET AL: "Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium", GENE THER. (1994), 1(1), 64-9 CODEN: GETHEC, 1994, XP000671119 *
PAUL D. ROBBINS ET AL.: "Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis", ANNAL NEW YORK ACADEMY OF SCIENCES, vol. 716, June 1993 (1993-06-01), pages 26 - 29, XP000565748 *
See also references of WO9420517A1 *
XIANG GAO ET AL.: "A novel cationic liposome reagent for efficient transfection of mammalian cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 179, no. 1, 30 August 1991 (1991-08-30), ORLANDO, FL US, pages 280 - 285, XP000572654 *

Also Published As

Publication number Publication date
EP0701563A1 (fr) 1996-03-20
JPH08511507A (ja) 1996-12-03
CA2157782A1 (fr) 1994-09-15
WO1994020517A1 (fr) 1994-09-15

Similar Documents

Publication Publication Date Title
WO1999064576A3 (fr) Nouveaux genes humains et produits d'expression genique
WO2002083945A3 (fr) Diagnostic et traitement du cancer
MY136603A (en) Biological products
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
EP2258722A3 (fr) Anticorps anti-polypeptides de type facteur de croissance des fibroblastes
WO2002062945A3 (fr) Compositions et techniques relatives a des genes et a des proteines specifiques du poumon
WO2001032910A3 (fr) 27 proteines humaines secretees
WO2002040672A3 (fr) Compositions et methodes relatives a des genes et des proteines specifiques aux seins
WO2000009754A3 (fr) COMPOSITIONS ASSOCIEES A LA STEAROYL-CoA DESATURASE HUMAINE ET PROCEDES DE TRAITEMENT D'AFFECTIONS CUTANEES
WO2000077239A3 (fr) Nouveaux genes codant pour des proteines a des fins de diagnostic, de prevention, de therapie et autres
RU97106340A (ru) Днк, кодирующая папиломавирус типа 6а человека
BR0210143A (pt) Fragmento de anticorpo recombinante, molécula de ácido nucleico, sequência de nucleotìdeo, processo para identificar fragmentos de anticorpo recombinante, uso do mesmo, preparação de agonistas contra a atividade biológica do ibdv, método para identificar um fragmento de anticorpo de ibdv recombinante, método para detectar a presença de anticorpo de ibdv em uma amostra, uso do mesmo, vetor, célula hospedeira recombinante, método para preparar um polipeptìdeo de anticorpo relacionado com o ibdv, conjunto para o diagnóstico de cepa do ibdv, composição terapêutica, método para tratar uma doença de ibdv, uso dos fragmentos de anticorpo recombinante
WO2002040673A3 (fr) Compositions et methodes relatives a des genes et des proteines specifiques aux poumons
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
WO2000061774A3 (fr) Proteines morphogeniques osseuses bmp
PT990000E (pt) Factor 3 de crescimento do tecido conjuntivo
DE69535091D1 (en) Humane prostacyclinsynthase
EP1593742A3 (fr) Vecteurs adénoviraux recombinants pour l'infection spécifique de céllules qui expriment des proteines fibreuses chimériques
WO2004013311A3 (fr) Compositions et methodes se rapportant a des genes et proteines specifiques de l'ovaire
WO2002088378A3 (fr) 66784, nouveau canal potassique humain et ses utilisations
WO2000043495A3 (fr) Proteines humaines secretees (33)
WO2001000638A3 (fr) Nouveaux genes codant des proteines pouvant etre utilisees dans des domaines diagnostiques, preventifs, therapeutiques ou autres
WO2001092495A3 (fr) Nouvelle lysyl oxydase humaine 47765 et ses utilisations
WO2002064788A3 (fr) Compositions et procedes relatifs aux genes et aux proteines specifiques aux poumons
MXPA02004825A (es) Genes especificamente expresados en celulas dendriticas humanas.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROBBINS, PAUL, D.

Inventor name: EVANS, CHRISTOPHER, H.

Inventor name: GLORIOSO, JOSEPH, C.

RHK1 Main classification (correction)

Ipc: C12N 15/86

A4 Supplementary search report drawn up and despatched

Effective date: 19970521

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010509

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030319